FINDING
SPARKS TREATMENT POSSIBILITY
IN DIFFUSE MIDLINE GLIOMA (DMG)1
The DMG landscape has changed. Biopsy and molecular profiling can identify the H3 K27M mutation in patients with DMG, expanding treatment possibilities through targeted therapy.2
Perform biopsy and molecular profiling to accurately diagnose DMG and identify mutations, such as H3 K27M, that inform prognosis and treatment decisions.3,4
The National Comprehensive Cancer Network® (NCCN®) recommends biopsy and molecular profiling in patients with imaging suggestive of high-grade glioma.3,4
Mutations in genes encoding H3, which produce the H3 K27M–mutant protein, are key molecular alterations in DMG. Identifying them enables proper diagnosis and classification.2
Biopsy provides the necessary tissue to molecularly confirm DMG diagnoses. It can offer high diagnostic yield with a low risk of permanent complications in appropriate patients.1,5-7
H3, histone 3; K, lysine; M, methionine.
References: 1. Sheikh SR, Recinos VM, Thompson EM, et al. The role of brainstem biopsy and targeted therapies in pediatric diffuse midline glioma/diffuse intrinsic pontine glioma. Front Oncol. 2024;14:1504440. 2. Sharie SA, Laban DA, Al-Hussaini M. Decoding diffuse midline gliomas: a comprehensive review of pathogenesis, diagnosis and treatment. Cancers (Basel). 2023;15(19):4869. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Pediatric Central Nervous System Cancers V.1.2026. © National Comprehensive Cancer Network, Inc. 2025. All rights reserved. Accessed July 24, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 4. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Central Nervous System Cancers V.3.2026. © National Comprehensive Cancer Network, Inc. 2026. All rights reserved. Accessed August 28, 2026. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. 5. Fu AY, Kavia J, Yadava Y, et al. Biopsy of diffuse midline glioma is safe and impacts targeted therapy: a systematic review and meta-analysis. Childs Nerv Sys. 2024;40(3):625-634. 6. Du H, Wang J, Liu Q, Luo G. Diagnostic yield, safety, and molecular-era clinical utility of stereotactic biopsy for brainstem lesions: a contemporary systematic review and meta-analysis. Front Surg. 2026;13:1-14. 7. He L, He D, Qi Y, et al. Stereotactic biopsy for brainstem lesions: a meta-analysis with noncomparative binary data. Cancer Control. 2021;28:10732748211059858. 8. MODEYSO™. Package insert. Jazz Pharmaceuticals, Inc; 2026.